NewAmsterdam Pharma Co N.V. (NAMS)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 19,145 | 2,978 | 29,111 | |
| Selling, general and administrative expenses | 27,264 | 27,152 | 18,412 | |
| Research and development expenses | 27,516 | 44,751 | 35,702 | |
| Total operating expenses | 54,780 | 71,903 | 54,114 | |
| Operating loss | -35,635 | -68,925 | -25,003 | |
| Interest income | 7,055 | 7,351 | 4,443 | |
| Foreign exchange gains/(losses) | 8,626 | 4,293 | 4,682 | |
| Fair value change - warrants | -2,590 | -13,762 | - | |
| Fair value change - earnout | - | -3,992 | - | |
| Change in fair value of earnout and warrants | - | - | 770 | |
| Loss before tax | -17,364 | -39,527 | -16,648 | |
| Loss for the period | -17,364 | -39,527 | - | |
| Unrealized gain/(loss) on available-for-sale securities, net of tax | -107 | -33 | - | |
| Income tax expense (benefit) | - | - | -1 | |
| Total comprehensive loss for the period, net of tax | -17,471 | -39,560 | -16,647 | |
| Earnings per share, basic | -0.15 | -0.34 | -0.18 | |
| Earnings per share, diluted | -0.15 | -0.34 | -0.18 | |
| Weighted average number of shares outstanding, basic | 118,556,492 | 116,124,941 | 94,754,140 | |
| Weighted average number of shares outstanding, diluted | 118,556,492 | 116,124,941 | 94,754,140 | |